Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
120 SAR | -2.12% |
|
-1.64% | +7.33% |
Jul. 11 | Tadawul All Share Index Finishes Week Flat | MT |
Jul. 03 | Goldman Sachs Raises Mouwasat Medical Services PT, Keeps at Neutral | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company is in a robust financial situation considering its net cash and margin position.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 30.69 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- Revenue estimates are regularly revised downwards for the current and coming years.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.33% | 6.4B | D | ||
-31.86% | 13.92B | B+ | ||
+4.98% | 11.91B | B+ | ||
-6.31% | 11.55B | B | ||
+11.39% | 11B | B+ | ||
+29.71% | 8.65B | B | ||
+19.71% | 7.52B | B- | ||
-9.73% | 7.28B | A- | ||
0.00% | 4.41B | - | - | |
+14.60% | 4.25B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4002 Stock
- Ratings Mouwasat Medical Services Company